Segall Bryant & Hamill, LLC Alkermes Plc. Transaction History

Segall Bryant & Hamill, LLC

$7.07 Billion
Q4 2024

A detailed history of Segall Bryant & Hamill, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 569,620 shares of ALKS stock, worth $20.4 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

569,620

Previous 1,183,100 51.85%

Holding current value

$20.4 Million

Previous $33.1 Million 50.53%

% of portfolio

0.23%

Previous 0.46%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$25.7 - $31.46 $15.8 Million - $19.3 Million	-613,480 Reduced 51.85%	569,620 $16.4 Million
Q3 2024 Nov 08, 2024	SELL	$23.01 - $28.55 $870,583 - $1.08 Million	-37,835 Reduced 3.1%	1,183,100 $33.1 Million
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $3.21 Million - $3.77 Million	138,469 Added 12.79%	1,220,935 $29.4 Million
Q1 2024 May 15, 2024	SELL	$26.4 - $32.56 $469,576 - $579,144	-17,787 Reduced 1.62%	1,082,466 $29.3 Million
Q4 2023 Feb 14, 2024	BUY	$23.37 - $28.68 $2.55 Million - $3.13 Million	109,084 Added 11.01%	1,100,253 $30.5 Million
Q3 2023 Nov 09, 2023	BUY	$27.17 - $31.97 $232,357 - $273,407	8,552 Added 0.87%	991,169 $27.8 Million
Q2 2023 Aug 11, 2023	SELL	$28.34 - $33.63 $169,189 - $200,771	-5,970 Reduced 0.6%	982,617 $30.8 Million
Q1 2023 May 15, 2023	BUY	$25.31 - $29.02 $12.1 Million - $13.9 Million	477,352 Added 93.37%	988,587 $27.9 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $11.2 Million - $13.4 Million	511,235 New	511,235 $13.4 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $9.8 Million - $14.2 Million	445,667 New	445,667 $9.95 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $20,196 - $23,363	765 Added 0.18%	431,061 $12.8 Million
Q1 2022 May 13, 2022	BUY	$23.07 - $27.99 $39,634 - $48,086	1,718 Added 0.4%	430,296 $11.3 Million
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $387,125 - $578,434	18,031 Added 4.39%	428,578 $9.97 Million
Q3 2021 Nov 03, 2021	BUY	$23.37 - $32.13 $191,587 - $263,401	8,198 Added 2.04%	410,547 $12.7 Million
Q2 2021 Aug 12, 2021	SELL	$18.78 - $25.15 $8,338 - $11,166	-444 Reduced 0.11%	402,349 $9.87 Million
Q1 2021 May 13, 2021	SELL	$18.21 - $23.2 $15,314 - $19,511	-841 Reduced 0.21%	402,793 $7.52 Million
Q4 2020 Feb 12, 2021	BUY	$15.39 - $22.1 $655,198 - $940,863	42,573 Added 11.79%	403,634 $8.05 Million
Q3 2020 Nov 13, 2020	BUY	$16.16 - $20.66 $2.3 Million - $2.94 Million	142,129 Added 64.92%	361,061 $5.98 Million
Q2 2020 Aug 14, 2020	BUY	$13.31 - $19.41 $1.01 Million - $1.47 Million	75,901 Added 53.07%	218,932 $4.25 Million
Q1 2020 May 14, 2020	BUY	$13.06 - $21.24 $1.87 Million - $3.04 Million	143,031 New	143,031 $2.06 Million

Others Institutions Holding ALKS

# of Institutions

372

Shares Held

175M

Call Options Held

140K

Put Options Held

143K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.9B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.

Account

Segall Bryant & Hamill, LLC Alkermes Plc. Transaction History